Skip to main content
L&C BIO Co., Ltd logo

L&C BIO Co., Ltd — Investor Relations & Filings

Ticker · 290650 ISIN · KR7290650001 KO Manufacturing
Open in API
Filings indexed 378 across all filing types
Latest filing 2023-03-10 Proxy Solicitation & In…
Country KR South Korea
Listing KO 290650

About L&C BIO Co., Ltd

http://www.lncbio.co.kr/?locale=en_US

L&C BIO Co., Ltd. is a biotechnology company specializing in regenerative medicine. The company develops, manufactures, and commercializes human tissue-based medical devices and allograft treatment materials. Its core operations include the processing, storage, and distribution of human tissues, with a focus on skin, musculoskeletal, and soft tissues, utilizing patented processing technologies. The company's product portfolio also extends to other medical devices and cosmetics. L&C BIO supports its activities through dedicated research and development centers and manufacturing facilities, including a human tissue plant and a pharmaceutical plant, to advance its pipeline and serve global markets.

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit proxies from shareholders for an upcoming Annual General Meeting (AGM). It contains details about the meeting, the agenda (such as approval of financial statements, election of directors, etc.), and instructions for electronic voting. While it includes financial data (financial statements), this is provided as part of the 'Management Reference' section required for the proxy solicitation process, not as a standalone financial report. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2023-03-10 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by L&C Bio. It details the date, location, and specific agenda items for the upcoming Annual General Meeting, including the approval of financial statements, election of directors, and appointment of audit committee members. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their votes on the listed agenda items.
2023-02-24 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from L&C Bio regarding a significant change (over 15%) in revenue or profit structure, which is a standard disclosure requirement in South Korean financial markets (DART system). It provides a summary of financial performance (revenue, operating profit, net income) comparing the current fiscal year to the previous one, along with reasons for the variance. This is an initial announcement of financial results rather than a full annual report or a transcript, fitting the definition of an Earnings Release (ER). FY 2022
2023-02-16 Korean
기타경영사항(자율공시)(연골성분 기반 바이오 잉크를 이용한 소이증 치료 목적 구조체 제작용 조성물 및 그 제조방법 특허권 취득)
Regulatory Filings Classification · 100% confidence The document is a voluntary disclosure (자율공시) by L&C Bio regarding the acquisition of a patent for a bio-ink composition used in treating microtia. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a simple announcement of a report publication. As it is a regulatory disclosure of a material corporate event (patent acquisition) filed with the exchange, it falls under the general regulatory filing category.
2023-01-27 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as the 5% rule filing). It details changes in share ownership by major shareholders and special related parties, including the purpose of holding (management influence) and specific transaction details. This falls under the 'Major Shareholding Notification' category.
2023-01-13 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from L&C Bio regarding the correction of a previously reported stock option grant ('주식매수선택권 부여에 관한 신고'). It details the cancellation of a specific stock option grant due to the resignation of an employee. This type of disclosure, which involves changes to capital structure or equity-based compensation plans, is classified as a regulatory filing under the RNS category as it does not fit into specific categories like Director's Dealing (which is for personal trades) or Share Issue (which is for new shares).
2023-01-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.